Catherine R Marinac1,2,3, Sandahl H Nelson4,5,6, Shirley W Flatt5, Loki Natarajan4,5, John P Pierce4,5, Ruth E Patterson4,5. 1. Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA. CatherineR_Marinac@dfci.harvard.edu. 2. Harvard TH Chan School of Public Health, Boston, MA, USA. CatherineR_Marinac@dfci.harvard.edu. 3. Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, USA. CatherineR_Marinac@dfci.harvard.edu. 4. Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, USA. 5. Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA. 6. Graduate School of Public Health, San Diego State University, San Diego, CA, USA.
Abstract
PURPOSE: To examine whether baseline sleep duration or changes in sleep duration are associated with breast cancer prognosis among early-stage breast cancer survivors in the multi-center Women's Healthy Eating and Living Study. METHODS: Data were collected from 1995 to 2010. Analysis included 3047 women. Sleep duration was self-reported at baseline and follow-up intervals. Cox proportional hazard models were used to investigate whether baseline sleep duration was associated with breast cancer recurrence, breast cancer-specific mortality, and all-cause mortality. Time-varying models investigated whether changes in sleep duration were associated with breast cancer prognosis. RESULTS: Compared to women who slept 7-8 h/night at baseline, sleeping ≥9 h/night was associated with a 48% increased risk of breast cancer recurrence (Hazard ratio [HR] 1.48, 95% Confidence interval [CI] 1.01, 2.00), a 52% increased risk of breast cancer-specific mortality (HR 1.52, 95% CI 1.09, 2.13), and a 43% greater risk of all-cause mortality (HR 1.43, 95% CI 1.07, 1.92). Time-varying models showed analogous increased risk in those who inconsistently slept ≥9 h/night (all P < 0.05), but not in those who consistently slept ≥9 h/night. CONCLUSIONS: Consistent long or short sleep, which may reflect inter-individual variability in the need for sleep, does not appear to influence prognosis among early-stage breast cancer survivors.
PURPOSE: To examine whether baseline sleep duration or changes in sleep duration are associated with breast cancer prognosis among early-stage breast cancer survivors in the multi-center Women's Healthy Eating and Living Study. METHODS: Data were collected from 1995 to 2010. Analysis included 3047 women. Sleep duration was self-reported at baseline and follow-up intervals. Cox proportional hazard models were used to investigate whether baseline sleep duration was associated with breast cancer recurrence, breast cancer-specific mortality, and all-cause mortality. Time-varying models investigated whether changes in sleep duration were associated with breast cancer prognosis. RESULTS: Compared to women who slept 7-8 h/night at baseline, sleeping ≥9 h/night was associated with a 48% increased risk of breast cancer recurrence (Hazard ratio [HR] 1.48, 95% Confidence interval [CI] 1.01, 2.00), a 52% increased risk of breast cancer-specific mortality (HR 1.52, 95% CI 1.09, 2.13), and a 43% greater risk of all-cause mortality (HR 1.43, 95% CI 1.07, 1.92). Time-varying models showed analogous increased risk in those who inconsistently slept ≥9 h/night (all P < 0.05), but not in those who consistently slept ≥9 h/night. CONCLUSIONS: Consistent long or short sleep, which may reflect inter-individual variability in the need for sleep, does not appear to influence prognosis among early-stage breast cancer survivors.
Authors: James M Clinton; Christopher J Davis; Mark R Zielinski; Kathryn A Jewett; James M Krueger Journal: J Clin Sleep Med Date: 2011-10-15 Impact factor: 4.062
Authors: J M Krueger; S Takahashi; L Kapás; S Bredow; R Roky; J Fang; R Floyd; K B Renegar; N Guha-Thakurta; S Novitsky Journal: Adv Neuroimmunol Date: 1995
Authors: Wayne A Bardwell; Loki Natarajan; Joel E Dimsdale; Cheryl L Rock; Joanne E Mortimer; Kathy Hollenbach; John P Pierce Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Hans K Meier-Ewert; Paul M Ridker; Nader Rifai; Meredith M Regan; Nick J Price; David F Dinges; Janet M Mullington Journal: J Am Coll Cardiol Date: 2004-02-18 Impact factor: 24.094
Authors: Ruth E Patterson; Shirley W Flatt; Nazmus Saquib; Cheryl L Rock; Bette J Caan; Barbara A Parker; Gail A Laughlin; Kirsten Erickson; Cynthia A Thomson; Wayne A Bardwell; Richard A Hajek; John P Pierce Journal: Breast Cancer Res Treat Date: 2010-01-14 Impact factor: 4.872
Authors: Laurence Leysen; Astrid Lahousse; Jo Nijs; Nele Adriaenssens; Olivier Mairesse; Sergei Ivakhnov; Thomas Bilterys; Eveline Van Looveren; Roselien Pas; David Beckwée Journal: Support Care Cancer Date: 2019-07-25 Impact factor: 3.603
Authors: Louise Strøm; Josefine T Danielsen; Ali Amidi; Ana Lucia Cardenas Egusquiza; Lisa Maria Wu; Robert Zachariae Journal: Front Neurosci Date: 2022-04-19 Impact factor: 5.152
Authors: Robert Zachariae; Ali Amidi; Malene F Damholdt; Cecilie D R Clausen; Jesper Dahlgaard; Holly Lord; Frances P Thorndike; Lee M Ritterband Journal: J Natl Cancer Inst Date: 2018-08-01 Impact factor: 13.506